Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KVA12123- Dose Escalation · 1 trial · 17 indications
Type and frequency of adverse events as assessed by CTCAE v4.0.
Type and frequency of treatment related adverse events as assessed by CTCAE v4.0.
Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD) of KVA12123 when administered alone and in combination with pembrolizumab in participants with advanced solid tumors (milligrams or milligrams/kilogram).
| Arm | Type | Description |
|---|---|---|
| KVA12123 Monotherapy Dose Escalation | EXPERIMENTAL | Part A will consist of dose escalation with KVA12123 administered as a single agent in participants with advanced solid tumors. |
| KVA12123 Plus Pembrolizumab Dose Escalation | EXPERIMENTAL | Part B will consist of dose escalation with KVA12123 administered in combination with a fixed dose of pembrolizumab. |
| KVA12123 Monotherapy Dose Expansion | EXPERIMENTAL | Part C will consist of dose expansion with KVA12123 administered as a single agent at the RP2D in participants with advanced solid tumors. |
| KVA12123 Plus Pembrolizumab Dose Expansion | EXPERIMENTAL | Part D will consist of dose expansion with KVA12123 administered at the RP2D in combination with a fixed dose of pembrolizumab. |
| Name | Type | Description |
|---|---|---|
| KVA12123 - Dose Escalation | DRUG | Ascending KVA12123 doses given as monotherapy by intravenous administration every 2 weeks of each 6-week cycle. |
| KVA12123 Plus Pembrolizumab - Dose Escalation | DRUG | Ascending KVA12123 doses given by intravenous administration every 2 weeks of each 6-week cycle in combination with a fixed dose of pembrolizumab administered once every 6 week cycle. |
| KVA12123 - Dose Expansion | DRUG | KVA12123 administered at the RP2D by intravenous administration every 2 weeks of each 6 week cycle. |
| KVA12123 Plus Pembrolizumab - Dose Expansion | DRUG | KVA12123 administered at the RP2D by intravenous administration every 2 weeks in combination with a fixed dose of pembrolizumab administered once every 6 week cycle. |
Inclusion Criteria 1. Willing and able to provide informed consent. 2. Be at least 18 years of age at the time of consent. 3. Has histologically or cytologically confirmed, locally advanced or metastatic solid tumor that has progressed or was non-responsive to standard of care therapy and for which...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
KVA12123 is an investigational small molecule being studied for the treatment of advanced solid tumors, including melanoma, carcinoma, sarcoma, lung, prostate, breast, colorectal, uterine, pancreatic, gastric, esophageal, thyroid, ovarian, kidney, and head and neck cancers. It is currently in Phase 1 clinical development.
KVA12123 is a small molecule designed to treat cancer. Its specific molecular target has not been disclosed. The drug is being evaluated alone and in combination with pembrolizumab in patients with advanced solid tumors.
KVA12123 is being developed by TuHURA Biosciences, Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with advanced solid tumors.
KVA12123 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for safety, tolerability, and preliminary efficacy in patients with advanced solid tumors.
KVA12123 is being studied in a Phase 1 clinical trial with the identifier NCT05708950. This trial, known as VISTA-101, evaluates KVA12123 alone and in combination with pembrolizumab in patients with advanced solid tumors. The trial has been completed and enrolled 40 participants.
Yes, KVA12123 is also known as TBS-2025. The clinical trial NCT05708950 is titled "A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)."